- Home
- TVRD vs MDXH Comparison
TVRD vs MDXH Comparison
Compare TVRD & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TVRD
- MDXH
- Stock Information
- Founded
- TVRD 2017
- MDXH 2003
- Country
- TVRD United States
- MDXH Belgium
- Employees
- TVRD N/A
- MDXH N/A
- Industry
- TVRD Biotechnology: Pharmaceutical Preparations
- MDXH
- Sector
- TVRD Health Care
- MDXH
- Exchange
- TVRD Nasdaq
- MDXH Nasdaq
- Market Cap
- TVRD 246.5M
- MDXH 203.4M
- IPO Year
- TVRD N/A
- MDXH 2021
- Fundamental
- Price
- TVRD $3.91
- MDXH $3.61
- Analyst Decision
- TVRD Buy
- MDXH Strong Buy
- Analyst Count
- TVRD 7
- MDXH 3
- Target Price
- TVRD $51.67
- MDXH $7.67
- AVG Volume (30 Days)
- TVRD 160.8K
- MDXH 210.9K
- Earning Date
- TVRD 11-13-2025
- MDXH 11-12-2025
- Dividend Yield
- TVRD N/A
- MDXH N/A
- EPS Growth
- TVRD N/A
- MDXH N/A
- EPS
- TVRD N/A
- MDXH N/A
- Revenue
- TVRD N/A
- MDXH $103,069,000.00
- Revenue This Year
- TVRD N/A
- MDXH $24.78
- Revenue Next Year
- TVRD N/A
- MDXH $21.20
- P/E Ratio
- TVRD N/A
- MDXH N/A
- Revenue Growth
- TVRD N/A
- MDXH 21.68
- 52 Week Low
- TVRD $3.78
- MDXH $1.35
- 52 Week High
- TVRD $43.65
- MDXH $5.33
- Technical
- Relative Strength Index (RSI)
- TVRD 21.48
- MDXH 39.42
- Support Level
- TVRD $3.78
- MDXH $2.75
- Resistance Level
- TVRD $4.15
- MDXH $4.98
- Average True Range (ATR)
- TVRD 0.31
- MDXH 0.28
- MACD
- TVRD 0.90
- MDXH -0.08
- Stochastic Oscillator
- TVRD 19.40
- MDXH 41.26
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.